ライフサイエンスコーパス: esophagogastric

1 1.6% of all patients, most frequently after esophagogastric (4.2%) and hepatopancreaticobiliary (3.6

2 In metastatic esophagogastric adenocarcinoma (EGA), the addition of pr

3 hemotherapy with trastuzumab for resectable, esophagogastric adenocarcinoma (EGA).

4 ative treatment for patients with resectable esophagogastric adenocarcinoma (EGA).

5 mal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA).

6 improves survival in patients with advanced esophagogastric adenocarcinoma and undifferentiated carc

7 ociated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment combinatio

8 d among patients with second-line metastatic esophagogastric adenocarcinoma.

9 in the second-line treatment for metastatic esophagogastric adenocarcinoma.

10 Esophagogastric adenocarcinomas (EAC) are obesity-associ

11 BRCA-associated histologies, namely lung and esophagogastric adenocarcinomas.

12 onditioning, a side-to-side stapled cervical esophagogastric anastomosis (<3% incidence of leak), and

13 astrostomy and side-to-side stapled cervical esophagogastric anastomosis after esophagectomy for the

14 nd postoperative advantages surround stapled esophagogastric anastomosis compared with the hand-sewn

15 Side-to-side stapled cervical esophagogastric anastomosis may reduce operation times a

16 An esophagogastric anastomosis was performed in 144 patient

17 Transhiatal esophagectomy with a cervical esophagogastric anastomosis was performed on approximate

18 astrostomy and side-to-side stapled cervical esophagogastric anastomosis.

19 ed blood flow to the gastric fundus prior to esophagogastric anastomosis.

20 Complications included esophagogastric anastomotic leak (n = 15, 36%), which un

21 hepatobiliary AND hepatopancreatobiliary AND esophagogastric AND recovery AND outcomes." Primary outc

22 rt of 449 patients with pancreatic, biliary, esophagogastric, and hepatocellular cancers, resistance

23 in patients who have HER2-negative, advanced esophagogastric cancer (AEGC).

24 sistance in HER2-positive (HER2+) metastatic esophagogastric cancer (mEGC).

25 anitumumab for Advanced and Locally Advanced Esophagogastric Cancer (REAL-3) will evaluate whether th

26 In 25 patients with esophagogastric cancer and 20 control subjects, receiver

27 ants are enriched in gastric and early-onset esophagogastric cancer and that germline testing should

28 t has the potential to improve survival from esophagogastric cancer by facilitating earlier detection

29 n ex vivo experiments in the headspace above esophagogastric cancer compared with the levels in sampl

30 herapy with 5-FU and cisplatin in resectable esophagogastric cancer improved pathologic complete resp

31 The role of ATM alterations in esophagogastric cancer risk warrants further investigati

32 ion of target volatile fatty acids (VFAs) in esophagogastric cancer through analysis of the ex vivo h

33 s (4.3%; 95% CI, 1.6%-9.1%) with early-onset esophagogastric cancer vs 5 (1.3%; 95% CI, 0.4%-3.1%; P

34 , to December 31, 2019, in 515 patients with esophagogastric cancer who consented to tumor and blood

35 tandard of care for patients with resectable esophagogastric cancer.

36 ne (EOC) is a standard treatment in advanced esophagogastric cancer.

37 0.4%-3.1%; P = .08) of those with late-onset esophagogastric cancer.

38 erioperative FLOT chemotherapy in resectable esophagogastric cancer.

39 A total of 337 patients had esophagogastric cancer: 83 in the surgical group and 254

40 noninvasive mixed-exhaled-breath testing for esophagogastric-cancer detection.

41 nt inhibitors into the treatment paradigm of esophagogastric cancers as well.

42 Among patients with esophagogastric cancers, only individuals who present wi

43 cancer genes in ovarian cancer, glioma, and esophagogastric carcinoma, respectively.

44 pleural mesothelioma, urothelial carcinoma, esophagogastric carcinoma, sarcoma, or glioblastoma mult

45 these innovations, portosystemic shunts and esophagogastric devascularization remain important and e

46 mmon indications for nonselective shunts and esophagogastric devascularization were medically intract

47 renal shunt (DSRS), nonselective shunts, and esophagogastric devascularization, was taken.

48 more protective against rebleeding than was esophagogastric devascularization.

49 roesophageal reflux disease (GERD) and other esophagogastric diseases.

50 patients with stage IV colorectal (CRC) and esophagogastric (EGC) cancer who were treated with first

51 were found in highest concentrations within esophagogastric-endoluminal air.

52 Transoral esophagogastric fundoplication (TF) can decrease or elim

53 Increasing numbers of patients are failing esophagogastric fundoplication and requiring redo proced

54 all bowel, cervical, colorectal, pancreatic, esophagogastric, hepatobiliary, and GI neuroendocrine ca

55 nts with adenocarcinoma of the esophagus and esophagogastric junction (AEG) is poor.

56 CC) of the esophagus, adenocarcinomas of the esophagogastric junction (AEG), or gastric cancer (GC).

57 .0) versus sham on esophageal physiology and esophagogastric junction (EGJ) anatomy.

58 In some patients, reflux at esophagogastric junction (EGJ) can be seen on the impeda

59 Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) is increasing, the earlie

60 Flow across the esophagogastric junction (EGJ) is strongly related to op

61 Distensibility of the esophagogastric junction (EGJ) largely determines esopha

62 etailed analysis of the mechanics leading to esophagogastric junction (EGJ) opening during transient

63 TBE accuracy for predicting achalasia/FLIP+ esophagogastric junction (EGJ) outflow obstruction, as d

64 pet (270 degrees wrap) fundoplication on the esophagogastric junction (EGJ) pressure in response to d

65 ip between obesity and the morphology of the esophagogastric junction (EGJ) pressure segment using hi

66 f achalasia hinges on demonstrating impaired esophagogastric junction (EGJ) relaxation and aperistals

67 Obstruction at the esophagogastric junction (EGJ) results in esophageal dil

68 ximal stomach above the meal adjacent to the esophagogastric junction (EGJ), referred to as the 'acid

69 tus) provide the sphincter mechanisms at the esophagogastric junction (EGJ).

70 and specialized populations of cells at the esophagogastric junction (residual embryonic cells and t

71 pic specialized intestinal metaplasia of the esophagogastric junction (SIM-EGJ).

72 nitial laparotomy, followed by harvesting of esophagogastric junction 60 days later.

73 with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local ther

74 The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvan

75 ize therapy for patients with esophageal and esophagogastric junction adenocarcinoma was effective, i

76 zed consecutive resections for esophageal or esophagogastric junction adenocarcinomas performed at tw

77 management of most resectable esophageal and esophagogastric junction adenocarcinomas.

78 ; 66 patients (75%) had EGA localized in the esophagogastric junction and 22 in the stomach (25%).

79 3-85.15 years) with biopsy-proved cancer (28 esophagogastric junction and 71 gastric cancers) were ex

80 hronic opioid use with motility disorders of esophagogastric junction and esophageal body peristalsis

81 ectal cancer (CRC), gastric cancer (GC), and esophagogastric junction cancer (EGJC)-is essential for

82 e found in 10-26% of gastric cancer (GC) and esophagogastric junction cancer (EGJC).

83 tients undergoing surgery for esophageal and esophagogastric junction cancers across 20 centers (NCT0

84 thy individuals and patients with gastric or esophagogastric junction cancers with sensitivity and sp

85 of HER2 status in tumor tissue in gastric or esophagogastric junction cancers.

86 is capable of selectively analyzing discrete esophagogastric junction contributors (lower esophageal

87 data for adenocarcinoma of the esophagus and esophagogastric junction demonstrate that lymphadenectom

88 RNA-sequencing analyses linked CM from esophagogastric junction fat of obese patient-induced HI

89 CM from esophagogastric junction fat of obese patients caused di

90 CM from esophagogastric junction fat of obese patients induced r

91 in short segments of columnar mucosa at the esophagogastric junction has clinical importance but can

92 g FLIP panometry protocol, interpretation of esophagogastric junction opening and contractile respons

93 (FLIP) panometry provides assessment of the esophagogastric junction opening and esophageal body con

94 BEST PRACTICE ADVICE 4: Normal esophagogastric junction opening on FLIP has a high nega

95 e findings supportive of achalasia, abnormal esophagogastric junction opening on FLIP should prompt f

96 re of esophageal emptying disorders, such as esophagogastric junction outflow obstruction and achalas

97 , and the development of diagnoses including esophagogastric junction outflow obstruction and hyperco

98 70.7% respectively; p < 0.001), particularly esophagogastric junction outflow obstruction disorders.

99 h negative predictive value for disorders of esophagogastric junction outflow obstruction on high-res

100 ents with adenocarcinoma of the esophagus or esophagogastric junction received neoadjuvant therapy.

101 Reduction or normalization of the esophagogastric junction relaxation pressure achieved by

102 that the disease process progresses from the esophagogastric junction to the esophageal body.

103 rapy for adenocarcinoma of the esophagus and esophagogastric junction using Worldwide Esophageal Canc

104 Capillary content of the esophagogastric junction was quantified using IHC for va

105 adenocarcinomas arising in the esophagus and esophagogastric junction, 56 Barrett adenocarcinomas, an

106 ders, injection of inert substances into the esophagogastric junction, and electrical stimulation of

107 ssion in adenocarcinomas of the esophagus or esophagogastric junction, few studies have assessed the

108 leted nCRT for carcinoma of the esophagus or esophagogastric junction, is not of major importance wit

109 carcinoma of the esophagus (n = 19), cardia (esophagogastric junction, n = 12), or subcardia (n = 6).

110 th resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either p

111 epends on alleviating the obstruction at the esophagogastric junction, the postintervention contracti

112 the work-up for patients with tumors of the esophagogastric junction.

113 tion of adenocarcinomas of the esophagus and esophagogastric junction.

114 for adenocarcinoma of the esophagus and the esophagogastric junction.

115 ip of the nasogastric tube was lodged at the esophagogastric junction.

116 supports the diagnosis of a disorder of EGJ [esophagogastric junction] outflow" (median response 8.5;

117 the treatment of patients with esophageal or esophagogastric-junction cancer is not well established.

118 ients with potentially curable esophageal or esophagogastric-junction cancer.

119 risks of esophageal adenocarcinoma (EAC) and esophagogastric junctional adenocarcinoma (EGJA).

120 significant dose and duration responses) and esophagogastric junctional adenocarcinoma (odds ratio =

121 n total, 581 participants with EAC, 213 with esophagogastric junctional adenocarcinoma, and 332 with

122 ogic subtypes of esophageal malignancy (EAC, esophagogastric junctional adenocarcinoma, and ESCC) in

123 ssessed and data from 5 index (aortic, major esophagogastric, liver, pancreatic, and pelvic resection

124 BEST PRACTICE ADVICE 3: Patients with esophagogastric outflow obstruction alone and/or nonacha

125 For esophagogastric reconstruction, different anastomotic te

126 come indicators and long-term survival after esophagogastric resections.

127 ed vagal control compared with patients with esophagogastric symptoms.

128 VTEs occurred postdischarge (from 17.9% for esophagogastric to 100% for endocrine operations).

129 athy, malnutrition, muscle wasting, ascites, esophagogastric variceal hemorrhage, spontaneous bacteri

130 ic complications in patients with documented esophagogastric varices undergoing OLT.

131 e TEE monitoring during OLT in patients with esophagogastric varices.